GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 7,218,628 shares, a decline of 33.7% from the May 14th total of 10,887,679 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average trading volume of 1,769,530 shares, the days-to-cover ratio is currently 4.1 days.

Institutional Investors Weigh In On GoodRx

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC raised its stake in shares of GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after acquiring an additional 5,201 shares during the period. Brevan Howard Capital Management LP raised its stake in shares of GoodRx by 7.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares during the period. Hirtle Callaghan & Co LLC raised its stake in shares of GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after acquiring an additional 6,869 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares during the period. Finally, Quarry LP purchased a new stake in shares of GoodRx in the 3rd quarter valued at approximately $33,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Mizuho reduced their target price on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Friday, February 27th. TD Cowen lifted their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Weiss Ratings downgraded shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 20th. Leerink Partners reaffirmed an “outperform” rating and set a $3.00 target price on shares of GoodRx in a research note on Thursday, February 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.81.

GoodRx Price Performance

Shares of GDRX stock opened at $2.73 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47. The firm’s 50-day moving average is $2.52 and its two-hundred day moving average is $2.48. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81. The company has a market capitalization of $935.22 million, a PE ratio of 45.51, a price-to-earnings-growth ratio of 1.23 and a beta of 1.61.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $194.01 million for the quarter, compared to the consensus estimate of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business’s revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 EPS. Analysts predict that GoodRx will post 0.17 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.